Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies

Journal of Hematology & Oncology

Peter Westervelt¹  Ali McBride² 

[1] Department of Medicine, Oncology Division, Washington University, St. Louis, MO, USA;Arthur G. James Cancer Hospital, The Ohio State University, Department of Pharmacy, Room 368 Doan Hall, Columbus, OH, 43210, USA

关键词: Uric acid;    Rasburicase;    Tumor lysis syndrome (TLS);    Solid tumors;    Prophylactic therapy;    Management;    Hematologic malignancies;    Adverse events;    Allopurinol;    Acute renal failure;   

Others  :  821814
DOI  :  10.1186/1756-8722-5-75

 received in 2012-09-13, accepted in 2012-11-30,  发布年份 2012

【 摘 要 】

Tumor lysis syndrome (TLS) is widely recognized as a serious adverse event associated with the cytotoxic therapies primarily used in hematologic cancers, such as Burkitt lymphoma and acute lymphoblastic leukemia. In recent years, TLS has been more widely observed, due at least in part to the availability of more effective cancer treatments. Moreover, TLS is seen with greater frequency in solid tumors, and particularly in bulky tumors with extensive metastases and tumors with organ or bone marrow involvement. The consequences of TLS include the serious morbidity and high risk of mortality associated with the condition itself. Additionally, TLS may delay or force an alteration in the patient’s chemotherapy regimen. The changing patterns of TLS, as well as its frequency, in the clinical setting, result in unnecessarily high rates of illness and/or fatality. Prophylactic measures are widely available for patients at risk of TLS, and are considered highly effective. The present article discusses the various manifestations of TLS, its risk factors and management options to prevent TLS from occurring.

【 授权许可】

   
2012 McBride and Westervelt; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Howard SC, Jones DP, Pui CH: The tumor lysis syndrome. N Engl J Med 2011, 364:1844-1854.
• [2]Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J, et al.: Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone–results of a multicenter phase III study. J Clin Oncol 2010, 28:4207-4213.
• [3]Wetzstein GA: Tumor lysis syndrome-a treatment guide. Oncology 2002, 5:31-4.
• [4]Joshita S, Yoshizawa K, Sano K, Kobayashi S, Sekiguchi T, Morita S, et al.: A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome. Intern Med 2010, 49:991-994.
• [5]Qian KQ, Ye H, Xiao YW, Bao YY, Qi CJ: Tumor lysis syndrome associated with chemotherapy in primary retroperitoneal soft tissue sarcoma by ex vivo ATP-based tumor chemo-sensitivity assay (ATP-TCA). Int J Gen Med 2009, 2:1-4.
• [6]Shenoy C: Acute spontaneous tumor lysis syndrome in a patient with squamous cell carcinoma of the lung. QJM 2009, 102:71-73.
• [7]Noh GY, Choe DH, Kim CH, Lee JC: Fatal tumor lysis syndrome during radiotherapy for non-small-cell lung cancer. J Clin Oncol 2008, 26:6005-6006.
• [8]Ajzensztejn D, Hegde VS, Lee SM: Tumor lysis syndrome after treatment with docetaxel for non-small-cell lung cancer. J Clin Oncol 2006, 24:2389-2391.
• [9]Kurt M, Onal IK, Elkiran T, Altun B, Altundag K, Gullu I: Acute tumor lysis syndrome triggered by zoledronic Acid in a patient with metastatic lung adenocarcinoma. Med Oncol 2005, 22:203-6.
• [10]Hochberg J, Cairo MS: Tumor lysis syndrome: current perspective. Haematologica 2008, 93:9-13.
• [11]Ahamed SM, Varma RS, Mathew T, Hamide A, Badhe BA: Spontaneous tumour lysis syndrome associated with non-Hodgkin's lymphoma–a case report. Indian J Pathol Microbiol 2006, 49:26-28.
• [12]Howard SC, Pui CH: Pitfalls in predicting tumor lysis syndrome. Leuk Lymphoma 2006, 47:782-785.
• [13]Coiffier B, Altman A, Pui CH, Younes A, Cairo MS: Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008, 26:2767-2778.
• [14]Cairo MS, Bishop M: Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004, 127:3-11.
• [15]Hande KR, Garrow GC: Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993, 94:133-139.
• [16]Mott FE, Esana A, Chakmakjian C, Herrington JD: Tumor lysis syndrome in solid tumors. Support Cancer Ther 2005, 2:188-191.
• [17]Krishnan G, D’Silva K, Al-Janadi A: Cetuximab-related tumor lysis syndrome in metastatic colon carcinoma. J Clin Oncol 2008, 26:2406-2408.
• [18]Godoy H, Kesterson JP, Lele S: Tumor lysis syndrome associated with carboplatin and paclitaxel in a woman with recurrent endometrial cancer. Int J Gynaecol Obstet 2010, 109:254.
• [19]Habib GS, Saliba WR: Tumor lysis syndrome after hydrocortisone treatment in metastatic melanoma: a case report and review of the literature. Am J Med Sci 2002, 323:155-157.
• [20]Castro MP, VanAuken J, Spencer-Cisek P, Legha S, Sponzo RW: Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature. Cancer 1999, 85:1055-1059.
• [21]Stoves J, Richardson D, Patel H: Tumour lysis syndrome in a patient with metastatic melanoma treated with biochemotherapy. Nephrol Dial Transplant 2001, 16:188-189.
• [22]Verma A, Mathur R, Chauhan M, Ranjan P: Tumor lysis syndrome developing intraoperatively. J Anaesthesiol Clin Pharmacol 2011, 27:561-563.
• [23]Opyrchal M, Figanbaum T, Ghosh A, Rajkumar V, Caples S: Spontaneous tumor lysis syndrome in the setting of B-cell lymphoma. Case Report Med 2010, 2010:610969. 1–3
• [24]Riccio B, Mato A, Olson EM, Berns JS, Luger S: Spontaneous tumor lysis syndrome in acute myeloid leukemia: two cases and a review of the literature. Cancer Biol Ther 2006, 5:1614-1617.
• [25]Barquero Romero J, Catalina Fernández I, Hernández Sáez C, Jiménez Morales JL, García de la Llana F: Spontaneous tumor lysis syndrome in a patient with non-Hodgkin's lymphoma. An Med Interna 2005, 22:387-389.
• [26]Sharma SK, Malhotra P, Kumar M, Sharma A, Varma N, Singh S: Spontaneous tumor lysis syndrome in acute lymphoblastic leukemia. J Assoc Physicians India 2005, 53:828-830.
• [27]Jasek AM, Day HJ: Acute spontaneous tumor lysis syndrome. Am J Hematol 1994, 47:129-131.
• [28]Lin CJ, Hsieh RK, Lim KH, Chen HH, Cheng YC, Wu CJ: Fatal spontaneous tumor lysis syndrome in a patient with metastatic, androgen-independent prostate cancer. South Med J 2007, 100:916-917.
• [29]Pentheroudakis G, O’Neill VJ, Vasey P, Kaye SB: Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours. Report of two cases. Support Care Cancer 2001, 9:554-557.
• [30]Woo IS, Kim JS, Park MJ, Lee MS, Cheon RW, Chang HM, et al.: Spontaneous acute tumor lysis syndrome with advanced gastric cancer. J Korean Med Sci 2001, 16:115-118.
• [31]Sklarin NT, Markham M: Spontaneous recurrent tumor lysis syndrome in breast cancer. Am J Clin Oncol 1995, 18:71-73.
• [32]Crittenden DR, Ackerman GL: Hyperuricemic acute renal failure in disseminated carcinoma. Arch Intern Med 1977, 137:97-99.
• [33]Kjellstrand CM, Cambell DC II, von Hartitzsch B, Buselmeier TJ: Hyperuricemic acute renal failure. Arch Intern Med 1974, 133:349-359.
• [34]Cairo MS, Coiffier B, Reiter A, Younes A, TLS Expert Panel: Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010, 149:578-586.
• [35]Kennedy LD, Koontz S, Rao K: Emerging role of rasburicase in the management of increased plasma uric acid levels in patients with hematologic malignancies. J Blood Med 2011, 2:1-6.
• [36]Michallet AS, Tartas S, Coiffier B: Optimizing management of tumor lysis syndrome in adults with hematologic malignancies. Support Cancer Ther 2005, 2:159-166.
• [37]Doherty M: New insights into the epidemiology of gout. Rheumatology (Oxford) 2009, 48(Suppl 2):ii2-ii8.
• [38]National Library of Medicine: MedlinePlus: Uric acid – bloodhttp://www.nlm.nih.gov/medlineplus/ency/article/003476.htm webcite
• [39]van den Berg H, Reintsema AM: Renal tubular damage in rasburicase: risks of alkalinisation. Ann Oncol 2004, 15:175-176.
• [40]Ablin A, Stephens BG, Hirata T, Wilson K, Williams HE: Nephropathy, xanthinuria, and orotic aciduria complicating Burkitt's lymphoma treated with chemotherapy and allopurinol. Metabolism 1972, 21:771-778.
• [41]Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B, et al.: Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001, 19:697-704.
• [42]Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, et al.: A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001, 97:2998-3003.
• [43]Elitek [package insert] sanofi-aventis U.S, LLC, Bridgewater, NJ; 2011.
• [44]Knoebel RW, Lo M, Crank CW: Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome. J Oncol Pharm Pract 2011, 17:147-154.
• [45]Giraldez M, Puto K: A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults. Eur J Haematol 2010, 85:177-179.
• [46]Vines AN, Shanholtz CB, Thompson JL: Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients. Ann Pharmacother 2010, 44:1529-1537.
• [47]Campara M, Shord SS, Haaf CM: Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach. J Clin Pharm Ther 2009, 34:207-213.
• [48]Reeves DJ, Bestul DJ: Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer. Pharmacotherapy 2008, 28:685-690.
• [49]Hutcherson DA, Gammon DC, Bhatt MS, Faneuf M: Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy. 2006, 26:242-247.
• [50]McDonnell AM, Lenz KL, Frei-Lahr DA, Hayslip J, Hall PD: Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy 2006, 26:806-812.
• [51]Trifilio S, Gordon L, Singhal S, Tallman M, Evens A, Rashid K, et al.: Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant 2006, 37:997-1001.
• [52]McBride A, Lathan SC, Boehmer L, Augustin KA, Butler SM, Westervelt PW: A comparative evaluation of single fixed-dosing and weight-based dosing of rasburicase for tumor lysis syndrome.  . Pharmacotherapy, in press
• [53]Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, et al.: A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 2011,  . Epub ahead of print
• [54]Jeha S, Kantarjian H, Irwin D, Shen V, Shenoy S, Blaney S, et al.: Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005, 19:34-38.
• [55]Lee AC, Li CH, So KT, Chan R: Treatment of impending tumor lysis with single-dose rasburicase. Ann Pharmacother 2003, 37:1614-1617.